Bayer AG

Industry

  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • OTC, Consumer
  • Digital Health
    • Artificial Intelligence
    • Disease Management
  • In Vitro Diagnostics

Other Names/Subsidiaries

  • Actus Therapeutics.
  • Algeta
  • AskBio
  • Asklepios BioPharmaceutical
  • Bayer Consumer Care
  • Bayer CropScience
  • Bayer HealthCare (formerly Intendis)
  • Bayer Pharma
  • Bayer Yakuhin
  • Berlex Biosciences
  • Berlex Laboratories
  • BlueRock Therapeutics
  • Brain Neurotherapy Bio
  • BrainVectis
  • CIS Bio International
  • Conceptus
  • Dihon Pharmaceutical Group
  • DIREVO Biotech
  • Intendis
  • Jenapharm
  • KaNDy Therapeutics
  • Lyondell (Polyols business)
  • Medrad
  • Metrika
  • Miles Laboratories
  • Monsanto Company
  • MyoKardia
  • NanoCor Therapeutics
  • Noria Therapeutics
  • Pathway Medical Technologies
  • Possis Medical
  • RoverMed BioSciences
  • Schering
  • Synpromics
  • Visible Genetics
  • Vividion Therapeutics
  • Vividion Therapeutics
  • Zeptosens
See more in Biomedtracker

Latest on Bayer AG

Scrip

Stock Watch: Bayer’s Movable Goalposts

 
• By Andy Smith

A Paradoxical Stock Move Of all the stock price reactions in the fourth-quarter 2024 earnings season, the last – that of Bayer – was the most perplexing. Bayer’s stock price opened up in Frankfurt by

Scrip

Bayer Rolls Up Its Sleeves But Turnaround Will Take Time

 
• By Kevin Grogan

Last year was a tough one for Bayer and 2025 is going to be even worse but CEO Bill Anderson has delivered an upbeat update for the beleaguered German group as it teeters on the patent cliff of Xarelt

Scrip

Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth

 
• By Mandy Jackson

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

Scrip

Five Companies Heading Toward 2030 With Wind At Their Back

 
• By Jessica Merrill and Edwin Elmhirst

The biopharmaceutical industry is heading into a tumultuous period from 2026-2030, which will be marked by the loss of exclusivity (LOE) in the US of some of the industry’s biggest-selling brands. But